Skip to main content

Advertisement

SpringerLink
Log in

Inhibition of vascular endothelial growth factor in the treatment of solid tumors

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Vascular endothelial growth factor (VEGF) is the term used for a family of tumor-derived angiogenic factors that mediate endothelial proliferation and vascular permeability. Preclinical models have demonstrated the essential nature of VEGF in the angiogenesis of solid tumor growth and metastasis, whereas pathologic investigations have revealed strong correlations between VEGF production, microvessel density, and overall aggressiveness of many human solid tumors. Recent advances in the understanding of the molecular mechanisms of VEGF action have led to successful models for intervention in VEGF-mediated pathways in therapy for solid tumors. These include antibodies to block the binding of VEGF to its cellular receptors, small-molecule chemical inhibitors of the tyrosine kinase functions of the VEGF receptors, and antisense nucleic acids to interfere with cellular production of VEGF. Clinical investigations are ongoing to test the value of VEGF-based intervention alone or in combination with other anticancer agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Fidler IJ: Cancer biology: invasion and metastasis. In Clinical Oncology, edn 2. Edited by Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. New York: Churchill Livingstone; 2000:29–53.

    Google Scholar 

  2. Holash J, Maisonpierre PC, Compton D, et al.: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994–1998.

    Article  PubMed  CAS  Google Scholar 

  3. Pluda JM: Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 1997, 24:203–218.

    PubMed  CAS  Google Scholar 

  4. Ferrara N, Houck K, Jakeman L, et al.: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992, 13:18–32.

    Article  PubMed  CAS  Google Scholar 

  5. Folkman J, Klagsburn M: Angiogenic factors. Science 1987, 235:442–447.

    Article  PubMed  CAS  Google Scholar 

  6. Neufield G, Cohen T, Gengrinovitch S, et al.: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13:9–22.

    Google Scholar 

  7. Dvorak HF, Nagy JA, Berse B, et al.: Vascular permeability factor, fibrin, and the pathogenesis of the tumor stroma formation. Ann N Y Acad Sci 1992, 667:110–111.

    Article  Google Scholar 

  8. Stacker SA, Caesar C, Baldwin ME, et al.: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001, 7:186–191.

    Article  PubMed  CAS  Google Scholar 

  9. Skobe M, Hawighorst T, Jackson DG, et al.: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001, 7:192–198.

    Article  PubMed  CAS  Google Scholar 

  10. Shweiki D, Itin A, Soffer D, et al.: Vascular endothelial cell growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843–845.

    Article  PubMed  CAS  Google Scholar 

  11. Laderoute KR, Alarcon RM, Brody MD, et al.: Opposing effects of hypoxia on expression of the angiogeneic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clin Cancer Res 2000, 6:2941–2950.

    PubMed  CAS  Google Scholar 

  12. Rak J, Mitsuhashi Y, Bayko L, et al.: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995, 55:4574–4580.

    Google Scholar 

  13. Kieser A, Welch HA, Brandner G, et al.: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor-expression. Oncogene 1994, 9:963–969.

    PubMed  CAS  Google Scholar 

  14. Chiarugi V, Magnelli L, Cinelli M, Ruggiero: Oncogenes, p53 and tumor angiogenesis. J Cancer Res Clin Oncol 1998, 124:523–525.

    Article  PubMed  CAS  Google Scholar 

  15. Harada H, Nakagawa K, Iwata S, et al.: Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res 1999, 59:3783–3789.

    PubMed  CAS  Google Scholar 

  16. Gnarra JR, Zhou S, Merrill MJ, et al.: Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A 1996, 93:10589–10594. The authors show that expression of the wild-type von Hippel-Lindau gene in renal cancer cells with a VHL mutation does not affect in vitro growth characteristics but leads to decreased expression of VEGF. This article provides important insight into the mechanism of oncogenesis in the von Hippel-Lindau syndrome and in most cases of sporadic renal cancer.

    Article  PubMed  CAS  Google Scholar 

  17. Siemeister G, Weindel, Mohrs K, et al.: Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 1996, 56:2299–2301.

    PubMed  CAS  Google Scholar 

  18. Pertovaara L, Kaipainen A, Mustonen T, et al.: Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 1994, 269:6271–6274.

    PubMed  CAS  Google Scholar 

  19. Donovan D, Harmey JH, Toomey D, et al.: TGF beta-1 regulation of VEGF production by breast cancer cells. Ann Surg Oncol 1997, 4:621–627.

    Article  PubMed  CAS  Google Scholar 

  20. Koochekpour S, Merzak A, Pilkington GJ: Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro. Cancer Lett 1996, 102:209–215.

    Article  PubMed  CAS  Google Scholar 

  21. Ryuto M, Ono M, Izumi H, et al.: Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells: Possible roles of SP-1. J Biol Chem 1996, 271:28220–28228.

    Article  PubMed  CAS  Google Scholar 

  22. Jackson JR, Minton JAL, Ho ML, et al.: Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin-1beta. J Rheumatol 1997, 24:1253–1259.

    PubMed  CAS  Google Scholar 

  23. Form DM, Auerbach, R: PGE2 and angiogenesis. Proc Soc Exp Biol Med 1983, 172:214–218.

    PubMed  CAS  Google Scholar 

  24. Ben-Av P, Crofford LJ, Wilder RL, Hla T: Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 1995, 372:83–87.

    Article  PubMed  CAS  Google Scholar 

  25. Harada S, Rodan SB, Rodan GA: Expression and regulation of vascular endothelial growth factor in osteoblasts. Clin Orthop 1995, 313:76–80.

    PubMed  Google Scholar 

  26. Harada S, Nagy JA, Sullivan KA, et al.: Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J Clin Invest 1994, 93:2490–2496.

    PubMed  CAS  Google Scholar 

  27. Diaz-Flores L, Gutierrez R, Valladares F, et al.: Intense vascular sprouting from rat femoral vein induced by prostaglandins E1 and E2. Anat Rec 1994, 238:68–76.

    Article  PubMed  CAS  Google Scholar 

  28. Melillo G, Musso T, Sica A, et al.: A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 1995, 182:1683–1693.

    Article  PubMed  CAS  Google Scholar 

  29. Chin K, Kurashima Y, Ogura T, et al.: Induction of vascular endothelial growth factor/vascular permeability factor by nitric oxide in human glioblastoma and hepatocellular cell lines. Oncogene 1997, 15:437–442.

    Article  PubMed  CAS  Google Scholar 

  30. Garcia-Cardena G, Folkman J: Is there a role for nitric oxide in tumor angiogenesis [editorial]? J Natl Cancer Inst 1998, 90:560–562.

    Article  PubMed  CAS  Google Scholar 

  31. Jain RK, Safabakhsh N, Sckell A, et al.: Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1998, 95:10820–10825.

    Article  PubMed  CAS  Google Scholar 

  32. Hyder SM, Murthy L, Stancel GM: Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 1998, 58:392–395.

    PubMed  CAS  Google Scholar 

  33. La Porta CA, Comolli R: Angiogenic capacity and lung-colonizing potential in vivo is increased in weakly metastatic B16F1 cells and decreased in highly metastatic BL6 cells by phorbol esters. Clin Exp Metastasis 1998, 16:399–405.

    Article  PubMed  CAS  Google Scholar 

  34. Brown LF, Detmar M, Claffey K, et al.: Keratinocyte-derived vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997, 79:233–269.

    PubMed  CAS  Google Scholar 

  35. Detmar M, Yeo KT, Nagy JA, et al.: Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol 1995, 105:44–50.

    Article  PubMed  CAS  Google Scholar 

  36. Plate KH, Breier G, Weich HA, et al.: Vascular endothelial growth factor and glioma angiogenesis:coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994, 59:520–529.

    Article  PubMed  CAS  Google Scholar 

  37. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumor angiogenesis factor in human glioma in vivo. Nature 1992, 359:845–848.

    Article  PubMed  CAS  Google Scholar 

  38. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP: Expression of vascular endothelial growth factor, its receptors and other angiogenic factors in human breast cancer. Cancer Res 1996, 56:2013–2016.

    PubMed  CAS  Google Scholar 

  39. Guidi AJ, Schnitt SJ, Fischer L, et al.: Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 1997, 80:1945–1953.

    Article  PubMed  CAS  Google Scholar 

  40. O’Brien T, Cranston D, Fuggle S, et al.: Different angiogenic pathways characterize superficial and invasive bladder cancers. Cancer Res 1995, 55:510–513.

    PubMed  CAS  Google Scholar 

  41. Warren RS, Yuan H, Matli MR, et al.: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995, 95:1789–1797.

    PubMed  CAS  Google Scholar 

  42. Takahashi Y, Kitadai Y, Bukana CD, et al.: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995, 55:3964–3968.

    PubMed  CAS  Google Scholar 

  43. Kondo Y, Arii S, Furutani M, et al.: Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinoma. Cancer 2000, 88:1820–1827.

    Article  PubMed  CAS  Google Scholar 

  44. Ugurel S, Rappl G, Tilgen W, et al.: Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001, 19:577–583.

    PubMed  CAS  Google Scholar 

  45. Graeven U, Fiedler W, Karpinski S, et al.: Melanoma-associated expression of vascular endothelial growth factor and its receptors Flt-1 and kdr. J Cancer Res Clin Oncol 1999, 125:621–629.

    Article  PubMed  CAS  Google Scholar 

  46. Kraft A, Weindel K, Ochs A, et al.: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999, 85:178–187.

    Article  PubMed  CAS  Google Scholar 

  47. Aoki Y and Tosato G: Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi’s sarcoma-associated herpesvirus-infected primary effusion lymphomas. Blood 1999, 94:4247–4254.

    PubMed  CAS  Google Scholar 

  48. Rockwell P, Neufeld G, Glassman A, et al.: In vitro neutralization of vscular endothelial growth factor activation of Flk-1 by a monoclonal antibody. Molec Cell Diff 1995, 3:91–109.

    CAS  Google Scholar 

  49. Parry TJ, Cushman C, Gallegos AM, et al.: Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res 1999, 27:2569–2577.

    Article  PubMed  CAS  Google Scholar 

  50. Kim KJ, Li B, Winer J, et al.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841–844. The authors report for the first time the ability of a monoclonal antibody specific for VEGF to inhibit in vivo tumor growth without any in vitro effects, and the finding of decreased microvessel density around tumors in vivo. This demonstrated that inhibition of the action of an angiogenic factor spontaneously produced by tumor cells could suppress tumor growth in vivo.

    Article  PubMed  CAS  Google Scholar 

  51. Asano M, Yukita A, Matsumoto T, et al.: Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121. Cancer Res 1995, 55:5296–5301.

    PubMed  CAS  Google Scholar 

  52. Bachelder RE, Crago A, Chung J, et al.: Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001, 61:5736–5740.

    PubMed  CAS  Google Scholar 

  53. Eppenberger U, Kueng W, Schlaeppi J-M, et al.: Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 1998, 16:3129–3136.

    PubMed  CAS  Google Scholar 

  54. Anan K, Morisaki T, Katano M, et al.: Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery 1996, 119:333–339.

    Article  PubMed  CAS  Google Scholar 

  55. Takahashi A, Sasake H, Kim SJ, et al.: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placental growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994, 54:4233–4237.

    PubMed  CAS  Google Scholar 

  56. Shibusa T, Shijubo N, Shosaku A: Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin Cancer Res 1998, 4:1483–1487.

    PubMed  CAS  Google Scholar 

  57. Fontanini G, Vignati S, Boldrini L, et al.: Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997, 3:861–865.

    PubMed  CAS  Google Scholar 

  58. Sauter ER, Nesbit M, Watson JC, et al.: Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res 1999, 5:775–782.

    PubMed  CAS  Google Scholar 

  59. Obermair A, Bancher-Todesca D, Bilgi S, et al.: Correlation of vascular endothelial growth factor expression and microvessel density in cervical intraepithelial neoplasia. J Natl Cancer Inst 1997, 89:1212–1216.

    Article  PubMed  CAS  Google Scholar 

  60. Fukuda S, Shirahama T, Imazono Y, et al.: Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer 1999, 85:1323–1330.

    Article  PubMed  CAS  Google Scholar 

  61. Toi M, Inada K, Suzuki H, et al.: Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 1995, 36:193–204.

    Article  PubMed  CAS  Google Scholar 

  62. Gasparini G, Toi M, Gion M, et al.: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997, 89:139–147.

    Article  PubMed  CAS  Google Scholar 

  63. Linderholm B, Tavelin B, Grankvist K, et al.: Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 1998, 16:3121–3128.

    PubMed  CAS  Google Scholar 

  64. Linderholm B, Grankvist K, Wilking N, et al.: Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 2000, 18:1423–1431. Tumor VEGF levels measured by an enzyme immunoassay on tumor cytosols were shown to be an independent predictor of overall survival following adjuvant therapy in 362 patients with primary node-positive breast cancer.

    PubMed  CAS  Google Scholar 

  65. Fontanini G, Vignati S, Boldrini L, et al.: Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997, 3:861–865.

    PubMed  CAS  Google Scholar 

  66. Volm M, Koomagi R, Mattern J: Prognostic value of vascular endothelial growth factor and its recptor Flt-1 in squamous cell lung cancer. Int J Cancer 1997, 74:64–68.

    Article  PubMed  CAS  Google Scholar 

  67. Imoto H, Osaki T, Taga S, et al.: Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998, 115:1007–1114.

    Article  PubMed  CAS  Google Scholar 

  68. Takahashi Y, Tucker SL, Kitadai Y, et al.: Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997, 132:541–546.

    PubMed  CAS  Google Scholar 

  69. Amaya H, Tanigawa N, Lu C, et al.: Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett 1997, 119:227–235.

    Article  PubMed  CAS  Google Scholar 

  70. Tokunaga T, Oshika Y, Abet Y, et al.: Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 1998, 77:998–1002.

    PubMed  CAS  Google Scholar 

  71. Ishigami SI, Arii S, Furutani M, et al.: Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998, 78:1379–1384.

    PubMed  CAS  Google Scholar 

  72. Maeda K, Nishiguchi Y, Yashiro M, et al.: Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med 2000, 5:373–378.

    PubMed  CAS  Google Scholar 

  73. Landriscina M, Cassano A, Ratto C, et al.: Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer 1998, 78:765–770.

    PubMed  CAS  Google Scholar 

  74. Maeda K, Chung YS, Ogawa Y, et al.: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77:858–863.

    Article  PubMed  CAS  Google Scholar 

  75. Saito H, Tsujitani S, Kondo A, et al.: Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma. Surgery 1999, 125:195–201.

    PubMed  CAS  Google Scholar 

  76. Tanigawa N, Amaya H, Matsumura M, et al.: Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol 1997, 15:826–832.

    PubMed  CAS  Google Scholar 

  77. Ikeda N, Adachi M, Taki T, et al.: Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 1999, 79:1553–1563.

    Article  PubMed  CAS  Google Scholar 

  78. Torimura T, Sato N, Ueno T, et al.: Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 1998, 29:986–991.

    Article  PubMed  CAS  Google Scholar 

  79. Zhou J, Tang ZY, Fan J, et al.: Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J Cancer Res Clin Oncol 2000, 126:57–61.

    Article  PubMed  CAS  Google Scholar 

  80. El-Assal ON, Yamanoi A, Soda Y, et al.: Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998, 27:1554–1562.

    Article  PubMed  CAS  Google Scholar 

  81. Borre M, Nerstrom B, Overgaard J: Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 2000, 206:1882–1890.

    Google Scholar 

  82. Crew JP, O’Brien T, Bradburn M, et al.: Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997, 57:5281–5285.

    PubMed  CAS  Google Scholar 

  83. Chow NH, Liu HS, Chan SH, et al.: Expression of vascular endothelial growth factor in primary superficial bladder cancer. Anticancer Res 1999, 19:4593–4597.

    PubMed  CAS  Google Scholar 

  84. Eisma RJ, Spiro JD, Kreutzer DL: Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg 1997, 174:513–517.

    Article  PubMed  CAS  Google Scholar 

  85. Wakisaka N, Wen QH, Yoshizaki T, et al.: Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma. Laryngoscope 1999, 109:810–814.

    Article  PubMed  CAS  Google Scholar 

  86. Smith BD, Smith GL, Carter D, et al.: Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 2000, 18:2046–2052.

    PubMed  CAS  Google Scholar 

  87. Salven P, Heikkila P, Anttonen A, et al.: Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Mod Pathol 1997, 10:1128–1133.

    PubMed  CAS  Google Scholar 

  88. Paley PJ, Staskus KA, Gebhard K, et al.: Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997, 80:98–106.

    Article  PubMed  CAS  Google Scholar 

  89. Yamamoto S, Konishi I, Mandai M, et al.: Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlations with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 1997, 76:1221–1227.

    PubMed  CAS  Google Scholar 

  90. Garzetti GG, Ciavattini A, Lucarini G, et al.: Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystoadenocarcinomas: relationship with MIBI immunostaining. Gynecol Oncol 1999, 73:396–401.

    Article  PubMed  CAS  Google Scholar 

  91. Shih C-H, Ozawa S, Ando N, et al.: Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000, 6:1161–1168.

    PubMed  CAS  Google Scholar 

  92. Bok RA, Halabi S, Fei DT, et al.: Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a Cancer and Leukemia group B study. Cancer Res 2001, 61:2533–2536.

    PubMed  CAS  Google Scholar 

  93. George DJ, Halabi S, Shepard TF, et al.: Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001, 7:1932–1936.

    PubMed  CAS  Google Scholar 

  94. Hazelton D, Nicosia RF, Nicosia SV: Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res 1999, 5:823–829.

    PubMed  CAS  Google Scholar 

  95. Franck-Lissbrant I, Haggstrom S, Damber JE, et al.: Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated rats. Endocrinology 1988, 139:451–456.

    Article  Google Scholar 

  96. Jackson MW, Bentel JM, Tilley WD: Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997, 157:2323–2328.

    Article  PubMed  CAS  Google Scholar 

  97. Ferrer FA, Miller LJ, Andrawis RI, et al.: Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998, 51:161–167.

    Article  PubMed  CAS  Google Scholar 

  98. Jain RK, Safabakhsh N, Sckell A, et al.: Endothelial cell death, angiogenesis, and microvascular function following castration in an androgen-dependent tumor: role of VEGF. Proc Natl Acad Sci U S A 1998, 181:10820–10825. Using an androgen-dependent tumor model, the authors showed that castration leading to tumor regression was associated with a decrease in VEGF expression. Apoptosis was observed in endothelial cells preceding the apoptosis occurring in neoplastic cells upon androgen withdrawal.

    Article  Google Scholar 

  99. Brown LF, Berse B, Jackman RW, et al.: Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993, 143:1255–1262.

    PubMed  CAS  Google Scholar 

  100. Denhart BC, Guidi AJ, Tognazzi K, et al.: Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysphagia. Lab Invest 1997, 77:659–664.

    PubMed  CAS  Google Scholar 

  101. Guidi AJ, Abu-Jawdeh G, Tognazzi K, et al.: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer 1996, 78:454–460.

    Article  PubMed  CAS  Google Scholar 

  102. Abu-Jawdeh GM, Faix JD, Niloff J, et al.: Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 1996, 74:1105–1115.

    PubMed  CAS  Google Scholar 

  103. Claffey KP, Brown LF, del Aguila LF, et al.: Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996, 56:172–181.

    PubMed  CAS  Google Scholar 

  104. Guidi AJ, Abu-Jawdeh G, Berse B, et al.: Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995, 87:1237–1245.

    Article  PubMed  CAS  Google Scholar 

  105. Brown LF, Berse B, Jackman RW, et al.: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995, 26:86–91.

    Article  PubMed  CAS  Google Scholar 

  106. Brown LF, Berse B, Jackman RW, et al.: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993, 53:4727–4735.

    PubMed  CAS  Google Scholar 

  107. Brekken RA, Overholser JP, Stastny VA, et al.: Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000, 60:5117–5124. The monoclonal antibody that blocks VEGF receptor 2 (Flk-1/kDR) blocked the VEGF-induced vascular permeability increase in guinea pig skin and inhibited the growth of newly injected and established human tumor xenografts in mice.

    PubMed  CAS  Google Scholar 

  108. Geng L, Donnelly E, McMahon G, et al.: Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001, 61:2413–2419.

    PubMed  CAS  Google Scholar 

  109. Im SA, Gomez-Manzano C, Fuey J, et al.: Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 1999, 59:895–900.

    PubMed  CAS  Google Scholar 

  110. Cheng SY, Huang HJ, Nagane M, et al.: Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1996, 93:8502–8507.

    Article  PubMed  CAS  Google Scholar 

  111. Saleh M, Stacker SA, Wilks AF: Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996, 56:393–401.

    PubMed  CAS  Google Scholar 

  112. Pavco PA, Bouhana KS, Gallegos AM, et al.: Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 2000, 6:2094–2103.

    PubMed  CAS  Google Scholar 

  113. Alon T, Hemo I, Itin A, et al.: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995, 1:1024–1028. The regression of retinal capillaries in neonatal rats exposed to high oxygen pressures is preceded by a cessation of VEGF production by nearby neuroglial cells. This occurs via selective apoptosis of endothelial cells. This effect could be reversed by intraocular injection of VEGF at the onset of experimental hyperoxia, supporting the hypothesis that this specific angiogenic factor acts as a vascular survival factor in vivo.

    Article  PubMed  CAS  Google Scholar 

  114. Benjamin L, Hemo I and Keshet E: A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998, 125:1591–1598.

    PubMed  CAS  Google Scholar 

  115. Benjamin LE, Golijanin D, Itin A, et al.: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999, 103:159–165.

    PubMed  CAS  Google Scholar 

  116. Takayama K, Ueno H, Nakanishi Y, Sakamoto T, et al.: Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 2000, 60:2169–2177.

    PubMed  CAS  Google Scholar 

  117. Kim K, Li B, Houck K, et al.: The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992, 7:53–64.

    PubMed  CAS  Google Scholar 

  118. Gordon MS, Margolin K, Talpaz M, et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001, 19:843–850.

    PubMed  CAS  Google Scholar 

  119. Kabbinavar FF, Wong JT, Ayala RE, et al.: The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice [abstract]. Proc Am Assoc Cancer Res 1995, 36:488.

    Google Scholar 

  120. Borgstrom P, Gold DP, Hillan KJ, et al.: Importance of VEGF for breast cancer angiogenesis in vivo: Implication from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999, 19:4203–4214.

    PubMed  CAS  Google Scholar 

  121. Margolin K, Gordon MS, Holmgren E, et al.: Phase Ib trial of intravenous recombinant monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001, 19:851–856.

    PubMed  CAS  Google Scholar 

  122. DeVore RF, Fehrenbacher L, Herbst RS, et al.: A randomized phase II trial comparing rhuMAbVEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC [abstract]. Proc ASCO 2000, 19:485a.

    Google Scholar 

  123. Bergsland E, Hurwitz H, Fehrenbacher L, et al.: A randomized phase II trial comparing rhuMAbVEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/ LV alone in patients with metastatic colorectal cancer. Proc ASCO 2000, 19:939.

    Google Scholar 

  124. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000, 343:905–914.

    Article  PubMed  CAS  Google Scholar 

  125. Sledge G, Miller K, Novotny W, et al.: A phase II trial of single-agent rhuMAbVEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patient with relapsed metastatic breast cancer [abstract]. Proc ASCO 2000, 19:3a.

    Google Scholar 

  126. Chen HX, Gore-Langton RE, Cheson BD: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology 2001, 15:1017–1024.

    PubMed  CAS  Google Scholar 

  127. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 1995, 333:1757–1763. This classic paper, a review of angiogenesis from the “father” of the field, provides an excellent background for more focused reading in this area.

    Article  PubMed  CAS  Google Scholar 

  128. Usman N, Blatt LM: Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J Clin Invest 2000, 106:1197–1202

    Article  PubMed  CAS  Google Scholar 

  129. Beigelman L, McSwiggen J, Draper K, et al.: Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J Biol Chem 1995, 270:25702–25708.

    Article  PubMed  CAS  Google Scholar 

  130. Kong H-L, Crystal RG: Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst 1998, 90:273–286. An excellent review that moves from general concepts of gene therapy through advantages of gene transfer strategies for antiangiogenesis therapy to description of individual inhibitors that are candidates for this approach.

    Article  PubMed  CAS  Google Scholar 

  131. Kleinman HK, Liau G: Gene therapy for antiangiogenesis. J Natl Cancer Inst 2001, 93:965–967.

    Article  PubMed  CAS  Google Scholar 

  132. Kerbel RS, Viloria-Petit A, Klement G, Rak J: ’Accidental’ anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000, 36:1248–1257. This review describes numerous agents developed to act via other mechanisms and subsequently discovered to have antiangiogenesis activity.

    Article  PubMed  CAS  Google Scholar 

  133. Sweeney CJ, Miller K, Sissons SE, et al.: The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001, 61:3369–3372.

    PubMed  CAS  Google Scholar 

  134. Boehm T, Folkman J, Browder T, O’Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390:404–407. In three murine models of endostatin-responsive tumors, multiple cycles of tumor regression and regrowth in the absence of the angiogenesis inhibitor led to prolonged tumor dormancy without further therapy. This supports the concept that antiangiogenic therapy does not induce acquired drug resistance.

    Article  PubMed  CAS  Google Scholar 

  135. Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 1991, 13:31–36.

    Article  PubMed  CAS  Google Scholar 

  136. Achilles E-G, Fernandez A, Allred EN, et al.: Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for “no take” of human tumors in mice. J Natl Cancer Inst 2001, 93:1075–1081.

    Article  PubMed  CAS  Google Scholar 

  137. Fidler I: Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J Natl Cancer Inst 2001, 93:1040–1041. This editorial contains a concise summary of the field of tumor heterogeneity as it affects proangiogenic products of tumor cells and their interaction with the organ microenvironment.

    Article  PubMed  CAS  Google Scholar 

  138. Yoshiji H, Harris SR, Thorgeirsson UP: Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 1997, 57:3924–3928.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 East Duarte Road, 91010, Duarte, CA, USA

    Kim Margolin D

Authors
  1. Kim Margolin D
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Margolin, K. Inhibition of vascular endothelial growth factor in the treatment of solid tumors. Curr Oncol Rep 4, 20–28 (2002). https://doi.org/10.1007/s11912-002-0044-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-002-0044-9

Keywords

Search

Navigation